Capecitabine or infusional 5-fluorouracil for gastroesophageal cancer: A cost-consequence analysis

Current Oncology

Volumn 18, Issue 2, 2011, Pages

  Horgan, A M ^a   Knox, J J ^a   Liu, G ^a   Sahi, C ^a   Bradbury, P A ^a   Leighl, N B ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Capecitabine; Cost consequence analysis; Gastroesophageal cancer; Infusional 5fu

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; SENSITIVITY ANALYSIS; THROMBOEMBOLISM; TREATMENT DURATION; VOMITING;

EID: 79955462058     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v18i2.730     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
3. Glimelius B, Hoffman K, Haglund U, Nyrén O, Sjödén PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994;5:189-190.
4. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
5. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate(FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591.
6. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-267.
7. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophago gastric cancer. J Clin Oncol 2002;20:1996-2004.
8. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
9. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115.
10. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
11. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III non in feriority trial. Ann Oncol 2009;20:666-673.
12. Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the real-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009;20:1529-1534.
13. Ng R, Hasan B, Mittmann N, et al. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage nonsmall- cell lung cancer-a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:2256-2261.
14. Ontario, Ministry of Health and Long-Term Care. Ontario Health Insurance (OHIP) Schedule of Benefits and Fees. Toronto, ON: Ministry of Health and Long-Term Care; 2007.
15. World Health Organization (WHO). The International Statistical Classification of Diseases and Related Health Problems. 10th rev (1992). Version for 2007. Geneva, Switzerland: 2007. [Available online at: http://apps.who.int/classifications/apps/icd/icd10online/;cited December 29, 2010]
16. Hoffmann-La Roche. Xeloda (capecitabine) Tablets [product monograph]. Basel, Switzerland: Hoffmann-La Roche; 2000. [Available online at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20896lbl.pdf cited January 27, 2011]
17. Benson AB 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22:2918-2926.
18. Noble SI, Shelley MD, Coles B, et al. Management of venous thrombo embolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol 2008;9:577-584.
19. Pazdur RCL, Hoskins WJ, Wagman LD, eds. Cancer Management- A Multidisciplinary Approach: Medical, Surgical and Radiation Oncology. 8th ed. Manhasset, NY: CMP Healthcare Media; 2004.
20. Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society, 2007. [Available online at: www.cancer.org/acs/groups/content/@nho/documents/document/globalfactsandfigures2007rev2p.pdf,cited December 27, 2010]
21. Garrison L, Cassidy J, Saleh M, et al. Cost comparison of XELOX compared to folfox-4 with or without bevacizumab (BEV) in metastatic colorectal cancer [abstract 4074]. J Clin Oncol 2007;25:. [Available online at: www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=36286; cited December 18, 2010]
22. Perrocheau G, Bennouna J, Ducreux M, et al. Cost-minimization analysis of a phase III study of capecitabine + oxaliplatin (XELOX) VS. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting [abstract 4083]. J Clin Oncol 2007; 25: [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=36039; cited December 18, 2010]
23. Chu E, Zelt S, Song X. A claims database cost-comparison analysis of capecitabine in the treatment of patients with colon or rectal cancer (CRC) [abstract 364]. Proc ASCO Gastrointest Cancer Symp 2008;:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10739; cited December 18, 2010]
24. Best JH, Garrison LP. Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer. Expert Rev Pharmacoecon Outcomes Res 2010; 10:103-114.